GESTIÓN EN SALUD PÚBLICA: Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

viernes, 20 de mayo de 2022

Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

Study finds important health outcomes are not included in cost-effectiveness analyses for sickle cell, Alzheimer’s and MS treatments

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)